Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"

Inclusion Criteria: * Volunteered to participate in this study and signed an informed consent form; * Men or non-pregnant women ≥ 18 and ≤75 years of age; * Lesion is located in a coronary artery and the need for coronary drug-eluting stent implantation; * Patients with persistent or permanent atrial fibrillation; * Score of CHA2DS2VASc≥2. Exclusion Criteria: * Severe liver and kidney diseases (GFR\<60 ml/min/1.73m2 or CTP≥6 score); * Moderate to severe hypertension (after standard antihypertensive therapy, blood pressure higher than 160/100mmHg); * Patients with hemodynamic or electrical instability (including shock); * Coagulation disorders associated with significant bleeding tendency (eg, hypersensitivity, active bleeding, moderate or severe liver disease, history of previous intracranial bleed, GI bleed within the past 6 months, major surgery within 30 days); * Patients with ischemic stroke within one week; * Patients with Bronchial asthma, Chronic obstructive pulmonary disease (COPD), and patients with diseases related to dyspnoea; * Any contraindication against the use of ticagrelor and other study drugs; * Platelet count less than 100 x 109/L; * Haemoglobin (Hb) level less than 100 g/L; * Researchers involved in the study and / or immediate family members; * Participation in another investigation drug or device study in the past 30 days before enrollment; * Involvement in the planning and conduct of the study (applies to staffs at study sites); * Suffering from oth…